Literature DB >> 9804975

Transcriptional and post-transcriptional regulation of complement factor I (CFI) gene expression in Hep G2 cells by interleukin-6.

J O Minta1, M Fung, B Paramaswara.   

Abstract

We have investigated the effects of IL-1 and IL-6 on human complement factor I (CFI) production by Hep G2 cells. IL-6 treatment caused a dose- and time-dependent increase in CFI secretion while IL-1 did not demonstrate such effects. The increase in CFI synthesis correlated with increase in CFI mRNA levels. The half-life of CFI mRNA in untreated cells was approx. 23 h and this was increased to 31 h (26% increase) following induction with IL-6. The IL-6 induced increase in CFI gene expression was inhibited by actinomycin D indicating regulatory effects at the level of transcription. Nuclear run-on experiments showed that IL-6 increased the rate of CFI gene transcription 4.2-fold. Transient transfection analysis of chloramphenicol acetyltransferase reporter gene constructs containing truncated segments of the 5'-flanking region of CFI gene showed that the cis-acting sequence(s) controlling the IL-6 inducible transcription resides in an 83 bp region located between -738 bp and -655 bp relative to the transcription start site. Our results indicate that the upregulation of CFI gene expression by IL-6 involves a coordinate effort at the level of transcription and mRNA stability, with the enhanced rate of transcription being the principal mechanism.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9804975     DOI: 10.1016/s0167-4781(98)00189-4

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  9 in total

1.  Enhanced expression of the complement factor H mRNA in proliferating human RPE cells.

Authors:  Norbert Kociok; Antonia M Joussen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-04-08       Impact factor: 3.117

2.  Transcriptional modulation of the human complement factor I gene in Hep G2 cells by protein kinase C activation.

Authors:  J Minta; M Fung
Journal:  Mol Cell Biochem       Date:  1999-11       Impact factor: 3.396

3.  C3 glomerulopathy associated to multiple myeloma successfully treated by autologous stem cell transplant.

Authors:  M A Hamzi; A Zniber; G E Badaoui; E Mahtat; Z Alhamany; R Bayahia; N Ouzeddoun
Journal:  Indian J Nephrol       Date:  2017 Mar-Apr

4.  Nonsense-codon-mediated decay in human hereditary complement C3 deficiency.

Authors:  Edimara S Reis; Victor Nudelman; Lourdes Isaac
Journal:  Immunogenetics       Date:  2003-11-25       Impact factor: 2.846

5.  Molecular characterization of homozygous hereditary factor I deficiency.

Authors:  G V Baracho; V Nudelman; L Isaac
Journal:  Clin Exp Immunol       Date:  2003-02       Impact factor: 4.330

6.  Rare genetic variants in the CFI gene are associated with advanced age-related macular degeneration and commonly result in reduced serum factor I levels.

Authors:  David Kavanagh; Yi Yu; Elizabeth C Schramm; Michael Triebwasser; Erin K Wagner; Soumya Raychaudhuri; Mark J Daly; John P Atkinson; Johanna M Seddon
Journal:  Hum Mol Genet       Date:  2015-03-18       Impact factor: 6.150

7.  Recovery of renal function succeeding stem cell transplant: a case of C3 Glomerulonephiritis secondary to monoclonal gammopathy.

Authors:  Camilla Aakjær Andersen; Niels Marcussen; Jon Waarst Gregersen
Journal:  Clin Kidney J       Date:  2013-11-04

8.  Predicting physiological aging rates from a range of quantitative traits using machine learning.

Authors:  Eric D Sun; Yong Qian; Richard Oppong; Thomas J Butler; Jesse Zhao; Brian H Chen; Toshiko Tanaka; Jian Kang; Carlo Sidore; Francesco Cucca; Stefania Bandinelli; Gonçalo R Abecasis; Myriam Gorospe; Luigi Ferrucci; David Schlessinger; Ilya Goldberg; Jun Ding
Journal:  Aging (Albany NY)       Date:  2021-10-29       Impact factor: 5.682

9.  Activation of innate anti-viral immune response genes in symptomatic benign prostatic hyperplasia.

Authors:  A A Madigan; K M Sobek; J L Cummings; W R Green; D J Bacich; D S O'Keefe
Journal:  Genes Immun       Date:  2012-09-06       Impact factor: 2.676

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.